Biopharmaceuticals Elevated to Pillar Industry! At This Roadshow, Industry Leaders Deliberate on the Inflection Point Dynamics of Innovative Drugs, Vaccines, and Medical Imaging

① When assessing the innovative pharmaceutical industry, one should not focus solely on short-term market fluctuations but rather emphasize a company’s technological barriers, clinical value, pipeline quality, commercialization strategy, and core capabilities in global partnerships. ② If a drug is developed merely for the sake of achieving R&D success, rather than addressing unmet medical needs, it is highly unlikely to be successfully licensed out (BD) or effectively commercialized.

cls.cnJun 3 23:57

Yimai Sunshine (02522) will provide cash loans to Yimai Yuntai and Wuhan Rong Gongshe.

Yimai Sunshine (02522) announced that on June 2, 2026, the Company (as lender) entered into a financial assistance agreement with Yimai Yuntai and Wuhan Ronggongshe (as borrowers). Pursuant to this agreement, the Company will provide cash loans totaling no more than RMB 32 million to Yimai Yuntai and Wuhan Ronggongshe (the “Financial Assistance”). This amount represents the combined borrowing limit for Yimai Yuntai and Wuhan Ronggongshe.

Zhitong FinanceJun 2 22:02

Deconstructing the Investment Logic of Innovative Pharmaceuticals and Decoding a New Paradigm for Growth | This Biopharmaceutical Listed Company Roadshow Is Coming Soon to Shanghai

① The biopharmaceutical industry, with its high value-added nature and strong innovation capabilities, has become one of the core sectors driving new-quality productive forces. ② Guests from multiple Hong Kong-listed companies will focus on today’s most prominent sub-sectors within biopharmaceuticals, drawing on current industry dynamics and corporate operational experience to provide an in-depth analysis of core strategies and practical approaches related to innovative drug R&D planning, product commercialization, and business development (BD) expansion.

cls.cnMay 28 19:58

Hong Kong Stock Movement | Yimai Sunshine (02522) Surged Over 5% Following the Strategic Launch of the Super Intelligent Agent for Brain CT in Collaboration with Yinghe Medical

Yimai Sunshine (02522) surged over 5%. As of the time of writing, it was up 4.99%, trading at HKD 8.2 with a turnover of HKD 16.2266 million.

Zhitong FinanceMay 14 14:52

Hong Kong Stock Ratings Summary: Orient Securities Maintains Buy Rating for Meitu

Cailian Press will regularly compile ratings and target prices from various institutions for Hong Kong stocks.

cls.cnMay 8 15:09

TFI Asset Management Reaffirms Their Buy Rating on Jiangxi Rimag Group Co., Ltd. Class H (2522)

TipRanksMay 8 13:35 · Ratings